• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clarifying the role of SONIA: supporting academic evidence on CDK4/6 inhibitor timing.

作者信息

Petroff Avi, Tannock Ian F, Goldstein Daniel A

机构信息

Department of Internal Medicine, Maimonides Medical Center, Brooklyn, NY, USA.

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

出版信息

Nat Rev Clin Oncol. 2025 Jul 28. doi: 10.1038/s41571-025-01063-5.

DOI:10.1038/s41571-025-01063-5
PMID:40721910
Abstract
摘要

相似文献

1
Clarifying the role of SONIA: supporting academic evidence on CDK4/6 inhibitor timing.阐明SONIA的作用：支持关于CDK4/6抑制剂使用时机的学术证据。
Nat Rev Clin Oncol. 2025 Jul 28. doi: 10.1038/s41571-025-01063-5.
2
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.晚期乳腺癌中CDK4/6抑制剂的早期与延迟使用
Nature. 2024 Dec;636(8042):474-480. doi: 10.1038/s41586-024-08035-2. Epub 2024 Nov 27.
3
Using bioinformatics and artificial intelligence to map the cyclin-dependent kinase 4/6 inhibitor biomarker landscape in breast cancer.利用生物信息学和人工智能绘制乳腺癌中细胞周期蛋白依赖性激酶4/6抑制剂生物标志物图谱。
Future Oncol. 2024 Dec;20(40):3519-3537. doi: 10.1080/14796694.2024.2419352. Epub 2024 Nov 12.
4
Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis.低HER2表达对晚期HR + /HER2-乳腺癌患者CDK4/6抑制剂治疗反应的影响：一项多中心真实世界数据分析
Arch Gynecol Obstet. 2025 Feb;311(2):423-427. doi: 10.1007/s00404-024-07761-2. Epub 2024 Oct 7.
5
Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.MEK与CDK4/6抑制剂联合在KRAS突变型结直肠癌模型中的体内外疗效。
Oncotarget. 2016 Jun 28;7(26):39595-39608. doi: 10.18632/oncotarget.9153.
6
Deciphering the differential impact of CDK4 mutations on abemaciclib binding in oral squamous cell carcinoma: a precision medicine approach.解读CDK4突变对口腔鳞状细胞癌中阿贝西利结合的差异影响：一种精准医学方法。
Ir J Med Sci. 2025 Jul 21. doi: 10.1007/s11845-025-03994-5.
7
Dual Inhibition of CDK4/6 and mTORC1 Establishes a Preclinical Strategy for Translocation Renal Cell Carcinoma.CDK4/6和mTORC1的双重抑制为易位性肾细胞癌确立了一种临床前策略。
bioRxiv. 2025 Jul 17:2025.07.11.663903. doi: 10.1101/2025.07.11.663903.
8
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer.激素受体阳性转移性乳腺癌中NF1改变与CDK4/6抑制剂耐药性的床旁到实验室的转化分析
EBioMedicine. 2025 Jun 26;118:105828. doi: 10.1016/j.ebiom.2025.105828.
9
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C.帕博西尼治疗CDK4或CDK6扩增肿瘤患者的II期研究：NCI-MATCH ECOG-ACRIN试验（EAY131）子方案Z1C的结果
Clin Cancer Res. 2025 Jan 6;31(1):56-64. doi: 10.1158/1078-0432.CCR-24-0036.
10
Management of Metastatic Hormone Receptor-Positive Breast Cancer Beyond CDK4/6 Inhibitors.CDK4/6抑制剂之外的转移性激素受体阳性乳腺癌的管理
Curr Oncol Rep. 2025 May 28. doi: 10.1007/s11912-025-01689-9.

本文引用的文献

1
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).欧洲肿瘤内科学会临床获益量表2.0版（ESMO-MCBS v2.0）
Ann Oncol. 2025 May 21. doi: 10.1016/j.annonc.2025.04.006.
2
The SONIA trial shows the power and challenges of academic research.索尼娅试验展现了学术研究的力量与挑战。
Nat Rev Clin Oncol. 2025 May;22(5):311-312. doi: 10.1038/s41571-025-01004-2.
3
Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending.抗癌药物的药理学类效应：降低医疗支出的机遇
BMJ Oncol. 2024 Jan 30;3(1):e000287. doi: 10.1136/bmjonc-2023-000287. eCollection 2024.
4
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.晚期乳腺癌中CDK4/6抑制剂的早期与延迟使用
Nature. 2024 Dec;636(8042):474-480. doi: 10.1038/s41586-024-08035-2. Epub 2024 Nov 27.
5
The tyranny of non-inferiority trials.非劣效性试验的暴政。
Lancet Oncol. 2024 Oct;25(10):e520-e525. doi: 10.1016/S1470-2045(24)00218-3.
6
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.MONARCH 3：阿贝西利作为晚期乳腺癌初始治疗。
J Clin Oncol. 2017 Nov 10;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2.
7
Palbociclib and Letrozole in Advanced Breast Cancer.帕博西尼联合来曲唑治疗晚期乳腺癌。
N Engl J Med. 2016 Nov 17;375(20):1925-1936. doi: 10.1056/NEJMoa1607303.
8
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.瑞博西尼作为激素受体阳性晚期乳腺癌的一线治疗方案
N Engl J Med. 2016 Nov 3;375(18):1738-1748. doi: 10.1056/NEJMoa1609709. Epub 2016 Oct 7.
9
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).一种标准化、通用且经过验证的方法，用于对预期从抗癌治疗中获得的临床获益程度进行分层：欧洲肿瘤内科学会临床获益程度量表（ESMO-MCBS）。
Ann Oncol. 2015 Aug;26(8):1547-73. doi: 10.1093/annonc/mdv249. Epub 2015 May 30.